| DB ID | MyCo_3025 |
| Title | Comparison of 1,3-β-d-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients |
| Year | 2016 |
| PMID | 27475024 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | Immunosuppressed mechanical ventilated critically ill patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This observational study without any specific intervention was reviewed and approved by the ethics committee of the university hospital Klinikum rechts der Isar, Technische Universität München, Germany, and all data were processed anonymously. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | This observational study was conducted at the medical ICU of the University Hospital Technische Universität München, Germany. We analyzed the medical records of all immunosuppressed patients with respiratory failure that were treated at the ICU between December 2014 and December 2015. All critically ill patients with mechanical ventilation (18 years or older) who fulfilled the criteria for immunosuppression (see below) were included in this study. All other patients were not analyzed in this study. Forty-nine immunosuppressed patients with respiratory failure who were treated at the ICU between December 2014 and December 2015 fulfilled the inclusion criteria. |
| Cohort No. | 49 |
| Age Group | 18-84 |
| P Value | p<0.001 |
| Sensitivity | 0.88 |
| Specificity | 0.82 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is an important cause of morbidity and mortality in immunosuppressed patients. Diagnosis of IPA is challenging given the lack of a single criterion standard test. Moreover, patients' complexity and accompanying signs and symptoms are in most cases nonspecific and may not be present until the disease is advanced or disseminated. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | ELISA Kit Platelia Aspergillus; Bio-Rad, Marnes-la-Coquette, France |
| Assay Data | FDA- Fungitell® beta-D-glucan (BDG) assay |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
